Seattle Genetics, Inc.(SGEN): For the most recent quarter end, Seattle Genetics, Inc. reported Annual Earnings of $-0.39. Based on the filings, last years Annual Earnings was, $-1. For the most recent quarter end, SGEN reported a surprise Earnings per Share of -14.71% . The consensus estimate for current quarter is $-0.42 and for the current fiscal year, the estimate is $-1.55. For the Next fiscal year, the estimate is $-1.27 based on the consensus.
Seattle Genetics, Inc. has received $-0.42 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-0.51 while the top line estimate is $-0.37 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -180%. Seattle Genetics, Inc. results fell short with a surprise EPS of -14.71% or $-0.05. The Actual EPS was $-0.39 compared to the Estimated EPS of $-0.34 during its most recent quarterly earnings.
Seattle Genetics Last issued its quarterly earnings results on Feb 9, 2017. The company reported $-0.39 EPS for the quarter, missing the analyst consensus estimate by $ -0.07. Analyst had a consensus of $-0.32. The company had revenue of $105.30 million for the quarter, compared to analysts expectations of $106.60 million. The companys revenue was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.
Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Clay B Siegall (President and CEO) sold 14,465 shares at 61.78 per share price.On Dec 15, 2016, Darren S Cline (EVP, Commercial) sold 10,000 shares at 63.80 per share price.On Dec 12, 2016, Eric Dobmeier (Chief Operating Officer) sold 12,500 shares at 65.95 per share price.
Seattle Genetics, Inc. (NASDAQ:SGEN) witnessed a decline in the market cap on Wednesday as its shares dropped 1.67% or 1.1 points. After the session commenced at $65.51, the stock reached the higher end at $65.98 while it hit a low of $64.255. With the volume soaring to 885,718 shares, the last trade was called at $64.58. The company has a 52-week high of $75.36. The company has a market cap of $9,141 million and there are 141,552,650 shares in outstanding. The 52-week low of the share price is $28.32.
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The companys lead product, ADCETRIS? (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.